PCN300 EVALUATION OF OVERALL SURVIVAL ASSOCIATED WITH CHANGE IN DOSING OF BORTEZOMIB, MELPHALAN, AND PREDNISONE REGIMEN IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A REAL-WORLD STUDY
May 1, 2019, 00:00
10.1016/j.jval.2019.04.418
https://www.valueinhealthjournal.com/article/S1098-3015(19)30610-2/fulltext
Title :
PCN300 EVALUATION OF OVERALL SURVIVAL ASSOCIATED WITH CHANGE IN DOSING OF BORTEZOMIB, MELPHALAN, AND PREDNISONE REGIMEN IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A REAL-WORLD STUDY
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)30610-2&doi=10.1016/j.jval.2019.04.418
First page :
Section Title :
Open access? :
No
Section Order :
10062